ArticleLeukemia2014
How to manage mantle cell lymphoma.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.Hematological oncology · 2021Trial
- A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.Haematologica · 2018Trial
- Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.International journal of hematology · 2017Trial
- Trial
- The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow.American journal of clinical pathology · 2022Article
- Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.Oncotarget · 2022Article
- Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.Cancers · 2021Article
- Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.Leukemia · 2021Article
- Computer-aided detection of mantle cell lymphoma onAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.British journal of haematology · 2020Article
- Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.Cancer medicine · 2019Observational
- Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.JCO clinical cancer informatics · 2019Article
- Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.European radiology · 2018Review
- Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Oncotarget · 2017Article
- ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells.Oncotarget · 2017Article
- Treatment of the elderly patient with mantle cell lymphoma.Hematology. American Society of Hematology. Education Program · 2016Review
- Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.Cancer immunology, immunotherapy : CII · 2016Article
- Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.Oncotarget · 2016Review
- The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Haematologica · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) is no longer a hopeless disease. Considered to carry a uniformly dismal prognosis so far, during the last years it has been rediscovered as a heterogeneous clinical and biological entity. Such a complexity has been highlighted by molecular genetics, unraveling different pathways of cell survival and progression. Concurrently, the application of new therapeutic paradigms including rituximab, high-dose cytarabine and stem cell transplantation dramatically improved treatment activity and the introduction of innovative targeted molecules has already led to new patient perspectives. In this completely new and continually evolving landscape, the clinical hemato-oncologist might feel disoriented on what are the best current strategies to handle such a critical disease and the gold standard therapeutic options for MCL. Here we address some burning questions on how to manage MCL patients, spacing from prognostic issues to the dilemma of personalized treatment in different scenarios of the disease: how to diagnose an MCL? Which are the fundamental staging procedures? What are the most reliable prognosticators? Is there a place for watch and wait? Which are the best treatment options for younger, elderly and frail patients? Which patients are addressable to high-dose therapy? What is the role of allogeneic transplantation? What is the most appropriate approach for relapsing disease in different categories of patients? What novelties are going to be introduced in the near future? The practical algorithms here discussed represent an evidence-based approach derived from results of multicenter and randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.